Elevance Health stock: UBS lifts target to USD 523 from USD 460

Published on 10/23/2026 at 15:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Leerink set USD 450 from USD 395 on October 22, 2026. Elevance Health stock costs EUR 396.15 on October 23, 2026, up 1.63 percent versus Xetra close.

Analyst target and dividend date

UBS lifted its Elevance Health target to USD 523 from USD 460 on October 22, 2026.
Elevance Health declared a USD 1.72 dividend on October 20, 2026, payable December 18, 2026.
Elevance Health stock costs EUR 396.15 at Lang & Schwarz on October 23, 2026 at 3:31 p.m. CEST, 1.63 percent above the Xetra close of October 22, 2026.

Modernes Krankenhaus-Campus mit Glasfassade und Patienten im Eingangsbereich — Elevance Health Krankenversicherungs-Campus US2855211023 zeigt modernen Gebäudeeingang mit weitläufiger Grünanlage unter blauem Himmel, Illustration mit AI erstellt.

UBS lifted its Elevance Health price target to USD 523 from USD 460 on October 22, 2026, according to MarketScreener. The target lies 18.28 percent above the USD 442.16 NYSE price at 9:37 a.m. EDT on October 23, 2026. At Lang & Schwarz, the stock was trading at EUR 396.15 on October 23, 2026 at 3:31 p.m. CEST, up 1.63 percent versus the Xetra close of October 22, 2026 at EUR 389.80.

Dividend sets the next dates

Elevance Health declared a fourth-quarter dividend of USD 1.72 per share on October 20, 2026. The dividend is payable on December 18, 2026 to shareholders of record on December 4, 2026, according to the company release dated October 21, 2026 from Elevance Health.

Stock stays near its yearly high

On the NYSE, Elevance Health traded at USD 442.16 on October 23, 2026 at 9:37 a.m. EDT. The USD 274.84 to USD 450.69 52-week range places the price 1.89 percent below its high and 60.88 percent above its low. The stock was up 27.02 percent since January 1 on October 22, 2026. Trading volume stood at 47,735 shares, while market capitalization was USD 95.9 billion.

Margins and membership remain key

Elevance Health's third-quarter 2026 benefit expense ratio improved 70 basis points year over year to 90.60 percent, while medical membership fell by 487,000 year over year to 44.9 million as of September 30, 2026. Those figures came from the company's October 21 release and give the higher target a counterweight: premium and service-fee growth must offset lower enrollment in several risk-based businesses.

Comparison with peers

Elevance Health: up 1.63 percent, P/E 18.96, market capitalization USD 95.9 billion.

Humana (NYSE, USD): down 0.84 percent, P/E 39.78, market capitalization USD 50.1 billion.

Cigna (NYSE, USD): down 0.66 percent, P/E 12.98, market capitalization USD 82.9 billion.

Target and trading position

The analyst target, dividend calendar and 52-week position give investors three separate reference points. The price sits close to the yearly high, while the latest membership figure remains the main operating counter-factor.

The stock was trading at EUR 396.15 at Lang & Schwarz on October 23, 2026 at 3:31 p.m. CEST, 1.63 percent above the Xetra close of October 22, 2026 at EUR 389.80. The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.